FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

l	lame and Address of Reporting Person*  mith Cynthia  st) (First) (Middle)			<u>Pr</u>	2. Issuer Name and Ticker or Trading Symbol     Protara Therapeutics, Inc. [ TARA ]      3. Date of Earliest Transaction (Month/Day/Year)     06/07/2024					(Ch	Relationship neck all appli Director Officer below	cable) or (give title	g Pers	on(s) to Issu 10% Ow Other (s below)	ner		
C/O PROTARA THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, 3RD FLOOR			4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)						Lin	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person						
(Street) NEW YO	ORK N	Y	10010	R	ule 1	10b5-	1(c)	Transa	ctio	on Ind	ication		Form to Person		e than	One Report	ting
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						to						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				Transaction ate Ionth/Day/Ye	Execution Date,		, Transaction Disposed Of (I Code (Instr. 5)		ties Acquired (A) or I Of (D) (Instr. 3, 4 and		Benefici	es Formally (D) (I) (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code			,	Amount	ount (A) or (D)		Transac	Transaction(s) (Instr. 3 and 4)			msu. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (	5. Num of Derivat Securit Acquir (A) or Dispos of (D) ( 3, 4 an		ve es ed ed nstr.	Expiration D	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$2.67	06/07/2024		A		10,000		(1)	06	5/06/2034	Common Stock	10,000	\$0	10,000	)	D	

## Explanation of Responses:

1. The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

## Remarks:

/s/ Mary Grendell, Attorney-infact

\*\* Signature of Reporting Person Date

06/10/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.